2025 Q4 -tulosraportti
Vain PDF
46 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 22 222 | - | - | ||
| 3 719 | - | - | ||
| 7 720 | - | - | ||
| 11 412 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sitten · MuokattuNew 100 or perhaps 200 times improved effect with AAV gene therapy in the heart. There may be results from the collaboration with AAViGen which was announced on May 27. These are not my words. It is Erik D Wiklund who says this in Friday's webcast 25.15 into the presentation. Cool collaboration, he says. The circVec technology from Circio and the new AAV capsids from AAViGen are complementary technologies. Complementary technologies mean technologies that complement, support, and strengthen each other so that together they provide greater value than they do individually. These capsids are said to have already been tested in primates with human cells. "Preclinical validation: The therapy has undergone extensive preclinical tests in large animal models and human-relevant models to ensure that gene expression is stable, safe, and effective." Not just a huge potential but probably also a shortcut towards clinical studies and collaboration with a big farma.- ·5 t sittenStock of the week: Circio https://www.investornytt.no/bors/er-dette-starten-pa-neste-mangedobling/534135 The next stock out is a company we have written a lot about. The reason the company has ground down from the 13-mark to around 9 kroner is a warrant period. With solid volume allowing a number of traders to go in and out with significant sums intraday, we now believe that Circio can make a new jump above 10 kroner. The Norwegian biotech company Circio Holding ASA (CRNA) has completed an unusually eventful three-month period on the Oslo Stock Exchange. Spring has been characterized by a comprehensive financial turnaround, strong scientific data on the international stage, and a share price marked by high volatility. The company, which develops circular RNA technology for next-generation gene and cell therapy, has quickly positioned itself for long-term development. From capital shortage to solid runway A short time ago, Circio was heavily affected by acute capital needs, but recent months have radically changed the financial picture. Through successful capital increases at the beginning of the year, including a rights issue and directed issues, the company has secured a solid capital injection. CEO Erik Digman Wiklund confirmed in connection with the approval of the annual report in April that the company has now secured a financial runway (cash runway) all the way to 2030. This gives Circio the necessary peace of mind to accelerate the development of its circVec platform without imminent financing fears. The next major financial chapter is unfolding right now through the exercise of the company's subscription rights program (warrants), under the ticker CRNAS. The exercise period started on May 26 and lasts until June 9, 2026. Here, investors get the opportunity to subscribe for new shares with a 20 percent discount based on the volume-weighted average price from mid-May. Management recently followed up with a live webcast to explain the process and the path forward into the clinical phase, and the market is now eagerly awaiting the final result of the subscription round in June. Scientific validation in Boston Alongside the financial measures, Circio has achieved major milestones in research and development. The company was selected to give a prestigious oral presentation at the annual ASGCT conference (American Society of Gene and Cell Therapy) in Boston in mid-May. This is considered the most important global arena for gene and cell therapy, and provides strong international recognition. The data presented in the USA attracted attention, especially the extensive in vivo studies showing that the company's circVec technology provides up to 50 times increased gene expression in the eye compared to conventional mRNA-based systems. To protect these groundbreaking discoveries, Circio submitted a comprehensive new patent application to the European Patent Office (EPO) on May 21, which further strengthens the company's intellectual property and commercial position. Geared for ascent – and acquisition? The massive financial changes, combined with the issuance of new shares and the allocation of warrants, have naturally left their mark on the trading pattern on the Oslo Stock Exchange. The share price has experienced significant fluctuations over the past three months, which is typical for biotech companies in a transformation phase where large quantities of new shares hit the market. At the end of May, the share is traded in the area around 9.00 kroner. During this period, the company also held its ordinary general meeting on May 8, and key employees and board members have carried out planned redemptions of restricted stock units (RSUs) and options, followed by standard insider sales to cover tax obligations. With cleared finances and solid scientific evidence, Circio is in the process of changing its status from an uncertain restructuring case to a fully financed development path. The focus is now on translating the strong lab results into clinical phases and exploring commercial partnerships with global pharmaceutical companies in the coming years.
·5 t sittenThe "unexpected problem" is that Circio Holding has had such a strong share price increase that many existing shareholders now do not have enough capital to exercise all their subscription rights in the rights issue. The company can theoretically raise around 560 million kroner, but some small shareholders lack the money needed to participate fully. Therefore, Circio has entered into guarantee agreements to ensure that at least 150 million kroner are raised. For existing shareholders, this becomes a dilemma: * Participate in the rights issue and inject more capital. * Sell the subscription rights. * Choose not to participate and accept dilution. The situation is quite special because the problem is not due to lack of interest, but that the share price rally has made the potential investment much larger than many had anticipated. Circio Holding has been one of the most discussed small-cap stocks on the Oslo Stock Exchange in the last year, with very large price movements and a sharp increase in the number of small shareholders. If you own Circio shares yourself, I can also explain what this rights issue specifically means for the value of your shares and subscription rights. Everyone knows what it means here?? But I know myself ok- ·5 t sittenStock of the week. Multi-bagger candidate. Today's editorial. https://www.investornytt.no/bors/er-dette-starten-pa-neste-mangedobling/534135
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
46 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten · MuokattuNew 100 or perhaps 200 times improved effect with AAV gene therapy in the heart. There may be results from the collaboration with AAViGen which was announced on May 27. These are not my words. It is Erik D Wiklund who says this in Friday's webcast 25.15 into the presentation. Cool collaboration, he says. The circVec technology from Circio and the new AAV capsids from AAViGen are complementary technologies. Complementary technologies mean technologies that complement, support, and strengthen each other so that together they provide greater value than they do individually. These capsids are said to have already been tested in primates with human cells. "Preclinical validation: The therapy has undergone extensive preclinical tests in large animal models and human-relevant models to ensure that gene expression is stable, safe, and effective." Not just a huge potential but probably also a shortcut towards clinical studies and collaboration with a big farma.
- ·5 t sittenStock of the week: Circio https://www.investornytt.no/bors/er-dette-starten-pa-neste-mangedobling/534135 The next stock out is a company we have written a lot about. The reason the company has ground down from the 13-mark to around 9 kroner is a warrant period. With solid volume allowing a number of traders to go in and out with significant sums intraday, we now believe that Circio can make a new jump above 10 kroner. The Norwegian biotech company Circio Holding ASA (CRNA) has completed an unusually eventful three-month period on the Oslo Stock Exchange. Spring has been characterized by a comprehensive financial turnaround, strong scientific data on the international stage, and a share price marked by high volatility. The company, which develops circular RNA technology for next-generation gene and cell therapy, has quickly positioned itself for long-term development. From capital shortage to solid runway A short time ago, Circio was heavily affected by acute capital needs, but recent months have radically changed the financial picture. Through successful capital increases at the beginning of the year, including a rights issue and directed issues, the company has secured a solid capital injection. CEO Erik Digman Wiklund confirmed in connection with the approval of the annual report in April that the company has now secured a financial runway (cash runway) all the way to 2030. This gives Circio the necessary peace of mind to accelerate the development of its circVec platform without imminent financing fears. The next major financial chapter is unfolding right now through the exercise of the company's subscription rights program (warrants), under the ticker CRNAS. The exercise period started on May 26 and lasts until June 9, 2026. Here, investors get the opportunity to subscribe for new shares with a 20 percent discount based on the volume-weighted average price from mid-May. Management recently followed up with a live webcast to explain the process and the path forward into the clinical phase, and the market is now eagerly awaiting the final result of the subscription round in June. Scientific validation in Boston Alongside the financial measures, Circio has achieved major milestones in research and development. The company was selected to give a prestigious oral presentation at the annual ASGCT conference (American Society of Gene and Cell Therapy) in Boston in mid-May. This is considered the most important global arena for gene and cell therapy, and provides strong international recognition. The data presented in the USA attracted attention, especially the extensive in vivo studies showing that the company's circVec technology provides up to 50 times increased gene expression in the eye compared to conventional mRNA-based systems. To protect these groundbreaking discoveries, Circio submitted a comprehensive new patent application to the European Patent Office (EPO) on May 21, which further strengthens the company's intellectual property and commercial position. Geared for ascent – and acquisition? The massive financial changes, combined with the issuance of new shares and the allocation of warrants, have naturally left their mark on the trading pattern on the Oslo Stock Exchange. The share price has experienced significant fluctuations over the past three months, which is typical for biotech companies in a transformation phase where large quantities of new shares hit the market. At the end of May, the share is traded in the area around 9.00 kroner. During this period, the company also held its ordinary general meeting on May 8, and key employees and board members have carried out planned redemptions of restricted stock units (RSUs) and options, followed by standard insider sales to cover tax obligations. With cleared finances and solid scientific evidence, Circio is in the process of changing its status from an uncertain restructuring case to a fully financed development path. The focus is now on translating the strong lab results into clinical phases and exploring commercial partnerships with global pharmaceutical companies in the coming years.
- ·5 t sittenThe "unexpected problem" is that Circio Holding has had such a strong share price increase that many existing shareholders now do not have enough capital to exercise all their subscription rights in the rights issue. The company can theoretically raise around 560 million kroner, but some small shareholders lack the money needed to participate fully. Therefore, Circio has entered into guarantee agreements to ensure that at least 150 million kroner are raised. For existing shareholders, this becomes a dilemma: * Participate in the rights issue and inject more capital. * Sell the subscription rights. * Choose not to participate and accept dilution. The situation is quite special because the problem is not due to lack of interest, but that the share price rally has made the potential investment much larger than many had anticipated. Circio Holding has been one of the most discussed small-cap stocks on the Oslo Stock Exchange in the last year, with very large price movements and a sharp increase in the number of small shareholders. If you own Circio shares yourself, I can also explain what this rights issue specifically means for the value of your shares and subscription rights. Everyone knows what it means here?? But I know myself ok
- ·5 t sittenStock of the week. Multi-bagger candidate. Today's editorial. https://www.investornytt.no/bors/er-dette-starten-pa-neste-mangedobling/534135
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 22 222 | - | - | ||
| 3 719 | - | - | ||
| 7 720 | - | - | ||
| 11 412 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
46 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten · MuokattuNew 100 or perhaps 200 times improved effect with AAV gene therapy in the heart. There may be results from the collaboration with AAViGen which was announced on May 27. These are not my words. It is Erik D Wiklund who says this in Friday's webcast 25.15 into the presentation. Cool collaboration, he says. The circVec technology from Circio and the new AAV capsids from AAViGen are complementary technologies. Complementary technologies mean technologies that complement, support, and strengthen each other so that together they provide greater value than they do individually. These capsids are said to have already been tested in primates with human cells. "Preclinical validation: The therapy has undergone extensive preclinical tests in large animal models and human-relevant models to ensure that gene expression is stable, safe, and effective." Not just a huge potential but probably also a shortcut towards clinical studies and collaboration with a big farma.
- ·5 t sittenStock of the week: Circio https://www.investornytt.no/bors/er-dette-starten-pa-neste-mangedobling/534135 The next stock out is a company we have written a lot about. The reason the company has ground down from the 13-mark to around 9 kroner is a warrant period. With solid volume allowing a number of traders to go in and out with significant sums intraday, we now believe that Circio can make a new jump above 10 kroner. The Norwegian biotech company Circio Holding ASA (CRNA) has completed an unusually eventful three-month period on the Oslo Stock Exchange. Spring has been characterized by a comprehensive financial turnaround, strong scientific data on the international stage, and a share price marked by high volatility. The company, which develops circular RNA technology for next-generation gene and cell therapy, has quickly positioned itself for long-term development. From capital shortage to solid runway A short time ago, Circio was heavily affected by acute capital needs, but recent months have radically changed the financial picture. Through successful capital increases at the beginning of the year, including a rights issue and directed issues, the company has secured a solid capital injection. CEO Erik Digman Wiklund confirmed in connection with the approval of the annual report in April that the company has now secured a financial runway (cash runway) all the way to 2030. This gives Circio the necessary peace of mind to accelerate the development of its circVec platform without imminent financing fears. The next major financial chapter is unfolding right now through the exercise of the company's subscription rights program (warrants), under the ticker CRNAS. The exercise period started on May 26 and lasts until June 9, 2026. Here, investors get the opportunity to subscribe for new shares with a 20 percent discount based on the volume-weighted average price from mid-May. Management recently followed up with a live webcast to explain the process and the path forward into the clinical phase, and the market is now eagerly awaiting the final result of the subscription round in June. Scientific validation in Boston Alongside the financial measures, Circio has achieved major milestones in research and development. The company was selected to give a prestigious oral presentation at the annual ASGCT conference (American Society of Gene and Cell Therapy) in Boston in mid-May. This is considered the most important global arena for gene and cell therapy, and provides strong international recognition. The data presented in the USA attracted attention, especially the extensive in vivo studies showing that the company's circVec technology provides up to 50 times increased gene expression in the eye compared to conventional mRNA-based systems. To protect these groundbreaking discoveries, Circio submitted a comprehensive new patent application to the European Patent Office (EPO) on May 21, which further strengthens the company's intellectual property and commercial position. Geared for ascent – and acquisition? The massive financial changes, combined with the issuance of new shares and the allocation of warrants, have naturally left their mark on the trading pattern on the Oslo Stock Exchange. The share price has experienced significant fluctuations over the past three months, which is typical for biotech companies in a transformation phase where large quantities of new shares hit the market. At the end of May, the share is traded in the area around 9.00 kroner. During this period, the company also held its ordinary general meeting on May 8, and key employees and board members have carried out planned redemptions of restricted stock units (RSUs) and options, followed by standard insider sales to cover tax obligations. With cleared finances and solid scientific evidence, Circio is in the process of changing its status from an uncertain restructuring case to a fully financed development path. The focus is now on translating the strong lab results into clinical phases and exploring commercial partnerships with global pharmaceutical companies in the coming years.
- ·5 t sittenThe "unexpected problem" is that Circio Holding has had such a strong share price increase that many existing shareholders now do not have enough capital to exercise all their subscription rights in the rights issue. The company can theoretically raise around 560 million kroner, but some small shareholders lack the money needed to participate fully. Therefore, Circio has entered into guarantee agreements to ensure that at least 150 million kroner are raised. For existing shareholders, this becomes a dilemma: * Participate in the rights issue and inject more capital. * Sell the subscription rights. * Choose not to participate and accept dilution. The situation is quite special because the problem is not due to lack of interest, but that the share price rally has made the potential investment much larger than many had anticipated. Circio Holding has been one of the most discussed small-cap stocks on the Oslo Stock Exchange in the last year, with very large price movements and a sharp increase in the number of small shareholders. If you own Circio shares yourself, I can also explain what this rights issue specifically means for the value of your shares and subscription rights. Everyone knows what it means here?? But I know myself ok
- ·5 t sittenStock of the week. Multi-bagger candidate. Today's editorial. https://www.investornytt.no/bors/er-dette-starten-pa-neste-mangedobling/534135
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 22 222 | - | - | ||
| 3 719 | - | - | ||
| 7 720 | - | - | ||
| 11 412 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt